Resolution of the CD56^negCD16^possubset from eBL children after chemotherapy. NK cell subsets were defined by CD56 and CD16 expression. The first time point was before chemotherapy, and the second and third time points were 3 and 9 months, respectively, after diagnosis (during remission). (A) Changes in the percentage of NK cells were defined as the number of NK cells (CD56^pos and/or CD16^pos)/total number of live lymphocytes. (B) Changes in the percentage of CD56^negCD16^pos NK cells at each time point for 2 eBL patients. (C) Cytograms for the 3 time points for patient “BL1.” Changes in activation (D) and NCR (E) markers over time for both eBL children (“BL1” and “BL2”) for CD56^negCD16^pos NK cells. (F) Plots of NKp30/NKp46, NKp30/2B4, and NKp46/2B4 coexpression for CD56^negCD16^pos NK cells from an eBL1 patient during the course of treatment, as well as for 3 healthy Nandi children.